Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Real World Experience with Ibrutinib and Idelalisib from ASH 2015
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content